Journal of Cardiac Failure
Volume 5, Issue 3 , Pages 178-187 , September 1999

Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials

  • Peter Carson, MD

      Affiliations

    • Veteran's Affairs Medical Center, Washington, District of Columbia USA
    • ,
  • Susan Ziesche, RN

      Affiliations

    • Veteran's Affairs Medical Center, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    • ,
  • Gary Johnson, MS

      Affiliations

    • Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    • ,
  • Jay N. Cohn, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Jay N. Cohn, MD, Cardiovascular Division, University of Minnesota Medical School, Box 508 UMHC, 420 Delaware Street SE, Minneapolis, MN 55455.
    • Veteran's Affairs Cooperative Studies Coordinating Center, West Haven, Connecticut, USA
    • ,
  • For The Vasodilator-heart Failure Trial Study Group

Received 2 June 1999 ,Revised 6 July 1999 ,Accepted 16 July 1999.

References 

  1. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973–1986: evidence for increasing population prevalence. Arch Intern Med. 1990;150:769–773
  2. Alexander M, Grumbach K, Selby J, Brown AF, Washington E. Hospitalization for congestive heart failure-explaining racial differences. JAMA. 1995;274:1037–1042
  3. Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs Medical System. N Engl J Med. 1993;329:621–627
  4. Gillum RF. Heart failure in the United States, 1970–1985. Am Heart J. 1987;113:1043–1045
  5. Gillum RF. Pathophysiology of hypertension in blacks and whites. Hypertension. 1979;1:468–475
  6. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med. 1986;314:1547–1552
  7. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310
  8. Veterans Administration Co-Operative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982;14(suppl S):97–101
  9. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707–1713
  10. Passon PG, Beuler JD. A simplified radiometric assay for norepinephrine and epinephrine. Anal Biochem. 1973;51:618–631
  11. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem. 1991;37:1811–1819
  12. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609–616
  13. Peniston RL, Lu DY, Papademetriou V, Fletcher RD. Severity of coronary artery disease in black and white veterans and likelihood of revascularization. J Am Coll Cardiol. 1994;23:299A; (abstr)
  14. Joint National Committee . The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1985;144:1045–1057
  15. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14–19
  16. Cohn JN, Archibald DG, Francis GS, Ziesche S, Franciosa JA, Harston WE, et al. Veterans Administration Cooperative Study on vasodilator therapy of heart failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation. 1987;75(suppl VI):49–54
  17. Johnson G, Carson P, Francis GS, Cohn JN  for the VHeFT VA Cooperative Studies Group. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril: Veterans Affairs Cooperative Study on Vasodilator Therapy on Heart Failure (V-HeFT II). Circulation. 1993;87(suppl VI):32–39
  18. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure: traits among urban blacks. Arch Intern Med. 1988;148:2013–2016
  19. Cody RJ, Court AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest. 1986;77:1441–1452
  20. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. In: Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive heart failure. ed 2. Circulation. 80:1989;p. 299–305
  21. Kaplan NM, Kem DC, Holland OB, Kramer NJ, Higgins J, Gomez-Sanchez C. The intravenous furosemide test: A simple way to evaluate renin responsiveness. Ann Intern Med. 1976;84:639–645
  22. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87(suppl VI):5–16
  23. Mills PJ, Dimsdale JG, Ziegler MG, Neleson RA. Racial differences in epinephrine and beta adrenergic receptors. Hypertension. 1995;25:88–91
  24. Pratt JH, Menatunga AK, Bowsher RR, Henry BP. The interaction of norepinephrine excretion with blood pressure and race in children. J Hypertens. 1992;10:93–96
  25. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension-I. Results of short-term titration with emphasis on racial differences in response. JAMA. 1982;248:1996–2003
  26. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension II. Results of long-term therapy. JAMA. 1982;248:2004–2011
  27. Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension. 1983;5(suppl III):36–42
  28. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. In: Hemodynamic equivalency to sodium nitroprusside. ed 2. Chest. 73:1978;p. 8–13
  29. Bauer JA, Fung H-L. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35–39
  30. Münzel T, Kurz S, Rajagopalan S, Martin T, Berrington WR, Thompson JA, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest. 1996;98:1465–1470
  31. Gogia H, Mehra A, Parikh S, Raman M, Uppal JA, Johnson JV, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575–1580

☆ All editorial decisions for this article, including selection of reviewers, were made by a guest editor. This policy applies to all articles with authors from the University of Minnesota.

☆☆ Supported by the Veterans Affairs Cooperative Studies Program, Washington, District of Columbia.

PII: S1071-9164(99)90001-5

Journal of Cardiac Failure
Volume 5, Issue 3 , Pages 178-187 , September 1999

Article Tools